LLY · CIK 0000059478
ELI LILLY & Co
Annual figures as reported, FY2014–FY2025. Ratios and growth rates derived on-page.
Pharmaceutical Preparations
Company profile
Revenue
$65.2B
▲ +44.7% vs FY2024
Net income
$20.6B
▲ +94.9% vs FY2024
Operating cash flow
$16.8B
▲ +90.7% vs FY2024
Diluted EPS
$22.95
▲ +96.0% vs FY2024
Revenue
Annual, as reported
Net income
Losses shown in terracotta
Recent quarters
momentum · last 12 quartersRevenue — Mar ’26 quarter
$19.8B
▲ +55.5% vs Mar ’25
Net income — Mar ’26 quarter
$7.4B
▲ +168.1% vs Mar ’25
Revenue — trailing 12 months
$72.2B
▲ +47.4% vs Mar ’25
Diluted EPS — trailing 12 months
$28.15
▲ +129.0% vs Mar ’25
Quarterly revenue
Discrete quarters; Q4 derived from the annual figure
Quarterly net income
Losses shown in terracotta
Profitability & returns
quality of earningsMargins
Share of revenue kept at each line
Gross marginNet margin
Returns on capital
Net income vs year-end equity and assets
Return on equityReturn on assets
Cash flow
cash generationOperating cash flow
Net cash from operations
Shareholder returns
capital allocationCapital returned
Cash paid out as dividends and share repurchases
Dividends paidBuybacks
Diluted shares outstanding
Falling count means buybacks outpace dilution
Balance sheet
financial positionStockholders’ equity
At fiscal year end
Net debt
Long-term debt less cash — negative means net cash
Growth rates
compounding, annualizedRevenue CAGR
+31.7%
3y
+21.6%
5y
+12.6%
10y
Net income CAGR
+49.0%
3y
+27.2%
5y
+24.0%
10y
Diluted EPS CAGR
+49.3%
3y
+27.6%
5y
+26.1%
10y
Share count change (split-adjusted)
−1.4%
5y
−15.6%
10y
Key ratios
derived per fiscal year| Fiscal year | Gross margin | Net margin | ROE | ROA | Current ratio | Debt / equity | DPS |
|---|---|---|---|---|---|---|---|
| FY2025 | 83.0% | 31.7% | 77.8% | 18.4% | 1.58× | 1.54× | $6.23 |
| FY2024 | 81.3% | 23.5% | 74.2% | 13.5% | 1.15× | 2.07× | $5.40 |
| FY2023 | 79.2% | 15.4% | 48.6% | 8.2% | 0.94× | 1.77× | $4.69 |
| FY2022 | 76.8% | 21.9% | 58.6% | 12.6% | 1.05× | 1.39× | $4.07 |
| FY2021 | 74.2% | 19.7% | 62.2% | 11.4% | 1.23× | 1.86× | $3.53 |
| FY2020 | 77.7% | 25.2% | 109.8% | 13.3% | 1.40× | 2.90× | $3.07 |
| FY2019 | 78.8% | 37.3% | 319.1% | 21.2% | 1.16× | 5.23× | $2.68 |
| FY2018 | 78.2% | 15.0% | 32.9% | 7.4% | 1.73× | 0.94× | $2.33 |
| FY2017 | 77.7% |
Annual figures
as reported| Fiscal year | Revenue | Gross profit | Op. income | Net income | Diluted EPS | Op. cash flow | Capex | Total assets | Liabilities | Equity | Cash | LT debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 | $65.2B | $54.1B | — | $20.6B | $22.95 | $16.8B | — | $112.5B | $85.9B | $26.5B | $7.3B | $40.9B |
| FY2024 | $45.0B | $36.6B | — | $10.6B | $11.71 | $8.8B | — | $78.7B | $64.4B | $14.3B | $3.3B | $29.5B |
| FY2023 | $34.1B | $27.0B | — | $5.2B | $5.80 | $4.2B | — | $64.0B | $53.2B | $10.8B | $2.8B | $19.1B |
| FY2022 | $28.5B | $21.9B | — | $6.2B | $6.90 | $7.6B | — | $49.5B | $38.8B | $10.6B | $2.1B | $14.8B |
| FY2021 | $28.3B | $21.0B | — | $5.6B | $6.12 | $7.4B | — | $48.8B | $39.8B | $9.0B | $3.8B | $16.7B |
| FY2020 | $24.5B | $19.1B | — |
Latest filings
the most recent regulatory filings144Notice of proposed insider sale2026-06-26 ↗11-KEmployee stock plan report2026-06-23 ↗4Insider ownership filing2026-06-16 ↗4Insider ownership filing2026-06-16 ↗4Insider ownership filing2026-06-16 ↗4Insider ownership filing2026-06-16 ↗
Company logos by Elbstream and unavatar.
All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.